Drugs affected by GCGR
About GCGR
GCGR is the receptor for glucagon. Retatrutide is the first incretin agonist to add glucagon-receptor activity to GLP-1 and GIP, and that combination is part of why phase 2 trials saw weight loss exceed any prior incretin agonist. So far no common GCGR variant has been shown to substantially change retatrutide response, but we surface the gene because the field is moving quickly.[1]
Active research area. We will surface phenotype guidance as the retatrutide literature matures.
Medications with GCGR information
This list contains 0 medications with GCGR information from the sources shown below. Evidence and report eligibility differ by drug; each page explains its scope and limitations.
References
- PharmGKB / Stanford University. PharmGKB: The Pharmacogenomics Knowledge Base. pharmgkb.org
Explore GCGR in your report
Informational only, not medical advice. The presence of a GCGR pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.